1

Supplemental Table 2. Ongoing clinical trials with anti-PD-1/PD-L1 therapy for breast cancer

Phase / Clinical trial registration / Breast cancer subtype / Disease setting / Drug name / Target
I / NCT02303366 / All / Metastatic / Pembrolizumab / Anti-PD-1
I/II / NCT02129556 / HER2+ / Metastatic / Pembrolizumab / Anti-PD-1
I/II / NCT02513472 / TNBC / Metastatic / Pembrolizumab / Anti-PD-1
II / NCT02411656 / TNBC or ER+/HER2− / Metastatic / Pembrolizumab / Anti-PD-1
II / NCT02447003 / TNBC / Metastatic / Pembrolizumab / Anti-PD-1
II / NCT02499367 / TNBC / Metastatic / Nivolumab / Anti-PD-1
II / NCT02411656 / HER2− / Metastatic / Pembrolizumab / Anti-PD-1
II / NCT02447003 / TNBC / Metastatic / Pembrolizumab / Anti-PD-1
II / NCT02395627 / HER2+ / Metastatic / Pembrolizumab / Anti-PD-1
II / NCT02648477 / TNBC and ER+/HER2− / Metastatic / Pembrolizumab / Anti-PD-1
III / NCT02555657 / TNBC / Metastatic / Pembrolizumab / Anti-PD-1
I / NCT02622074 / TNBC / Neoadjuvant / Pembrolizumab / Anti-PD-1
II / NCT01042379 / All / Neoadjuvant / Pembrolizumab / Anti-PD-1
I / NCT02309177 / TNBC, ER+/HER2− / Metastatic / Nivolumab / Anti-PD-1
I / NCT00836888 / All / Metastatic / Nivolumab / Anti-PD-1
I / NCT01848834 / TNBC / Metastatic / Pembrolizumab / Anti-PD-1
I / NCT02054806 / All / Metastatic / Pembrolizumab / Anti-PD-1
I/II / NCT02318901 / HER2+ / Metastatic / Pembrolizumab / Anti-PD-1
I/II / NCT02178722 / TNBC / Metastatic / Pembrolizumab
INCB024360 / Anti-PD-1
IDO inhibitor
I/II / NCT02657889 / TNBC / Metastatic / Pembrolizumab / Anti-PD-1
I/II / NCT02331251 / TNBC and ER+/HER2− / Metastatic / Pembrolizumab / Anti-PD-1
I/II / NCT01928394 / TNBC / Metastatic / Pembrolizumab+/- Ipilimumab / Anti-PD-1
CTLA-4
I/II / NCT02452424 / TNBC / Metastatic / Pembrolizumab
PLX3397 / Anti-PD-1
anti-CSF1R
I/II / NCT02331251 / All / Metastatic / Pembrolizumab / Anti-PD-1
I/II / NCT02318901 / HER2+ / Metastatic / Pembrolizumab
Atezolizumab / Anti-PD-1
Anti-PD-L1
I/II / NCT02404441 / All / Metastatic / PDR001 Durvalumab / Anti-PD-1
Anti-PD-L1
II / NCT02661100 / All / Metastatic / Pembrolizumab
CDX-1401 and
Poly-ICLC / Anti-PD-1
I / NCT02605915 / HER2+ / Metastatic and neoadjuvant / Atezolizumab / Anti-PD-L1
I / NCT02649686 / HER2+ / Metastatic / Atezolizumab / Anti-PD-L1
I / NCT02536794 / TNBC, ER+/HER2− / Metastatic / Durvalumab
Tremelimumab / Anti-PD-L1
CTLA-4
III / NCT02425891 / TNBC / Metastatic / Atezolizumab / Anti-PD-L1
I/II / NCT02489448 / TNBC / Neoadjuvant / Durvalumab / Anti-PD-L1
II / NCT02530489 / TNBC / Neoadjuvant / Atezolizumab / Anti-PD-L1
III / NCT02620280 / TNBC / Neoadjuvant / Atezolizumab / Anti-PD-L1
I / NCT01375842 / TNBC / Metastatic / Atezolizumab / Anti-PD-L1
I / NCT02655822 / TNBC / Metastatic / Atezolizumab
CPI-444 / Anti-PD-L1
I / NCT01772004 / All / Metastatic / Avelumab / Anti-PD-L1
I / NCT01975831 / ER+/HER2− and HER2+ / Metastatic / Durvalumab
Tremelimumab / Anti-PD-L1
CTLA-4
I / NCT02658214 / TNBC / Metastatic / Durvalumab
Tremelimumab / Anti-PD-L1
CTLA-4
I/II / NCT02543645 / TNBC / Metastatic / Atezolizumab
Varlilumab / Anti-PD-L1
CD27 agonist
I/II / NCT02543645 / TNBC / Metastatic / Atezolizumab
Varlilumab / Anti-PD-L1
CD27 agonist
I/II / NCT02403271 / TNBC and HER2+ / Metastatic / Durvalumab / Anti-PD-L1
I/II / NCT02643303 / All / Metastatic / Durvalumab and
Poly-ICLC +/-
Tremelimumab / Anti-PD-L1
CTLA-4
II / NCT02527434 / TNBC / Metastatic / Tremelimumab
Durvalumab / Anti-PD-L1
CTLA-4
II / NCT02478099 / TNBC / Metastatic / Atezolizumab / Anti-PD-L1
II / NCT02685059 / TNBC / Neoadjuvant / Durvalumab / Anti-PD-L1
I / NCT02725489 / TNBC / Metastatic and neoadjuvant / Durvalumab / Anti-PD-L1
II / NCT02752685 / HER2− / Metastatic / Pembrolizumab / Anti-PD-1